A Phase IV Study in Drug-Naive Patients With T2DM in China

PHASE4TerminatedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

May 24, 2019

Study Completion Date

May 24, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.

DRUG

Acarbose

Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.

Trial Locations (20)

100003

Research Site, Shenyang

100020

Research Site, Beijing

100730

Research Site, Beijing

200233

Research Site, Shanghai

215004

Research Site, Suzhou

230022

Research Site, Hefei

250012

Research Site, Jinan

266003

Research Site, Qingdao

310014

Research Site, Hangzhou

310016

Research Site, Hangzhou

400016

Research Site, Chongqing

410013

Research Site, Changsha

510280

Research Site, Guangzhou

610041

Research Site, Chengdu

710061

Research Site, Xi'an

750004

Research Site, Yinchuan

2100008

Research Site, Nanjing

Unknown

Research Site, Qingdao

CN-200120

Research Site, Shanghai

CN-300070

Research Site, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY